Table 1.
Anticancer treatment following study drug discontinuation in the ITT population and by receipt of induction chemotherapya.
| ITT population | With induction therapy | Without induction therapy | ||||
|---|---|---|---|---|---|---|
| Pertuzumab plus trastuzumab arm | Trastuzumab arm | Pertuzumab plus trastuzumab arm | Trastuzumab arm | Pertuzumab plus trastuzumab arm | Trastuzumab arm | |
| Patients, n (%) | (n = 129) | (n = 129) | (n = 75) | (n = 73) | (n = 54) | (n = 56) |
| Received anticancer therapy | ||||||
| Yes | 105 (81.4) | 109 (84.5) | 62 (82.7) | 57 (78.1) | 43 (79.6) | 52 (92.9) |
| No | 19 (14.7) | 19 (14.7) | 11 (14.7) | 15 (20.5) | 8 (14.8) | 4 (7.1) |
| Missing | 5 (3.9) | 1 (0.8) | 2 (2.7) | 1 (1.4) | 3 (5.6) | 0 |
| Anticancer therapies in ≥10% of patients in either arm, INN classb | ||||||
| Antiestrogens | 19 (18.1) | 27 (24.8) | 13 (21.0) | 9 (15.5) | 6 (14.0) | 18 (34.6) |
| Antimetabolites | 36 (34.3) | 27 (24.8) | 23 (37.1) | 16 (28.1) | 13 (30.2) | 11 (21.2) |
| Antineoplastic agents | 12 (11.4) | 11 (10.1) | 8 (12.9) | 7 (12.3) | 4 (9.3) | 4 (7.7) |
| AIs | 50 (47.6) | 49 (45.0) | 30 (48.4) | 27 (47.4) | 20 (46.5) | 22 (42.3) |
| Cytotoxic antibiotics | 10 (9.5) | 5 (4.6) | 8 (12.9) | 4 (7.0) | 2 (4.7) | 1 (1.9) |
| Monoclonal antibodies | 79 (75.2) | 79 (72.5) | 45 (72.6) | 42 (73.7) | 34 (79.1) | 37 (71.2) |
| Surgical and medical procedures | 19 (18.1) | 20 (18.3) | 11 (17.7) | 15 (26.3) | 8 (18.6) | 5 (9.6) |
| Taxanes | 18 (17.1) | 22 (20.2) | 8 (12.9) | 7 (12.3) | 10 (23.3) | 15 (28.8) |
| Tyrosine kinase inhibitors | 25 (23.8) | 19 (17.4) | 16 (25.8) | 13 (22.8) | 9 (20.9) | 6 (11.5) |
| Vinca alkaloids | 23 (21.9) | 24 (22.0) | 13 (21.0) | 13 (22.8) | 10 (23.3) | 11 (21.2) |
| Subsequent first-line treatment with HER2-targeted therapiesc | 61 (47.3) | 67 (51.9) | 32 (42.7) | 32 (43.8) | 29 (53.7) | 35 (62.5) |
| Pertuzumab plus trastuzumab | 20 (32.8) | 9 (13.4) | 10 (31.3) | 3 (43.8) | 10 (34.5) | 6 (17.1) |
| Ado-trastuzumab emtansine | 22 (36.1) | 11 (16.4) | 14 (43.8) | 5 (15.6) | 8 (27.6) | 6 (17.1) |
| Trastuzumab | 23 (37.7) | 50 (74.6) | 10 (31.3) | 24 (75.0) | 13 (44.8) | 26 (74.3) |
Abbreviation: INN, international nonproprietary name.
aSome therapies began before the last date of study treatment.
bA treatment may appear in more than one INN class.
cPatients may be counted in more than one category.